Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer

LIU YANG-fan; GAO JIAN-bu

doi:10.13422/j.cnki.syfjx.2011.05.083

您当前的位置：

首页 >

文章列表页 >

Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer

更新时间：2024-09-23

- Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 17, Issue 5, Pages: 231-232(2011)
- 作者机构：
  
  南阳市中心医院肿瘤科
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2011.05.083
  CLC： R734.2
- Published：2011
- 稿件说明：
移动端阅览
[1]刘扬帆,高建步.参芪扶正注射液联合多西他赛治疗中晚期非小细胞肺癌[J].中国实验方剂学杂志,2011,17(05):231-232.

LIU YANG-fan, GAO JIAN-bu. Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(5): 231-232.
[1]刘扬帆,高建步.参芪扶正注射液联合多西他赛治疗中晚期非小细胞肺癌[J].中国实验方剂学杂志,2011,17(05):231-232. DOI： 10.13422/j.cnki.syfjx.2011.05.083.

LIU YANG-fan, GAO JIAN-bu. Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(5): 231-232. DOI： 10.13422/j.cnki.syfjx.2011.05.083.

摘要

目的:运用参芪扶正注射液配合化疗

观察化疗患者骨髓抑制、消化道反应、KPS评分变化。方法:将符合纳入标准的肺癌化疗病人100例

应用信封法随机分组

实验组应用PD方案化疗

同时配合使用参芪扶正注射液;对照组单纯应用PD方案化疗。观察参芪扶正注射液对化疗所致的骨髓抑制、消化道反应、KPS体力状况评分的影响。结果:实验组WBC

NEU降低程度明显小于对照组（P<0.05）;实验组恶心、腹泻症状明显轻于对照组（P<0.05）;实验组KPS体力状况评分降低程度极明显小于对照组（P<0.01）。结论:参芪扶正注射液能减轻化疗后血WBC、NEU的下降程度

减轻化疗引起的恶心、腹泻症状

改善化疗后患者的KPS体力状况评分。

Abstract

Objective:The influence of the Shenqi Fuzheng injection to the patients who got the injection to go with the chemotherapy in hematology change

digestive response

the KPS grades along and after chemotherapy.Method:One-hundred patients were selected according to the standard of the lung cancer chemotherapy.With the quantization random controlled method

we devided the patients into two groups.The treatment group patients re-ceived the administration of Shenqi Fuzheng injection and、PD chemotherapy.The control group patients received only PD chemotherapy.We observed the influence of Shenqi Fuzheng injection on the aspects of myelosuppression

the response to chemotherapy in gastrointestinal and the KPS.Result:The reduce of the white blood cell（WBC）

the neutrophilic granulocyte（NEU） in the treatment group were lower than the control group obviously（P < 0.05）;The response to chemotherapy in gastrointestinal of the treatment group was lighter than the control group（P < 0.05）;The reduce of KPS were lower than the control group obviously（P < 0.01）.Conclusion:Shenqi Fuzheng in-jection can reduce the decrease of WBC

NEU after the chemotherapy

Shenqi Fuzheng injection can reduce the chemotherapy-induced nausea and diarrhea

Shenqi Fuzheng injection can improve the patient ’s KPS physical strength condition

关键词

Keywords

references

Views

167

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Determination of the Effect of Shenqi Fuzheng Injection on the Balance of Th1/Th2 by Cytometric Bead Array in S-bearing Mice with Chemotherapy

The Attenuation of Shenqi Fuzheng Injection Treatment on Immunosuppression Caused by Chemotherapeutics

Clinical Observation in Patient with Non-small Cell Lung Cancer Treated with Jiajian Shashen Maidong Decoction Integrated with Chemotherapy

Related Author

LIU YANG-fan

GAO JIAN-bu

丁治国1

史晓光1

李兰芳2

汪唐顺1

陈振宙1

张建松1

Related Institution

Henan Province Central Hospital of Nanyang City

Anshun City People’s Hospital

Henan Province Hospital of Traditional Chinese Medicine

The Second Clinical Medical College， Henan University of Chinese Medicine

The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰